1 / 4

Global Top 13 Companies Accounted for 63% of total Azilsartan Medoxomil API market (QYResearch, 2021)

Azilsartan medoxomil (trade name Edarb) is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. The global key manufacturers of Azilsartan Medoxomil API include Takeda, Metrochem API, Jubilant Pharma, Zhejiang Hongyuan, Honour Lab, HEC Pharm, Enomark, Lupin, CTX Life Sciences, Acura Labs, etc. In 2022, the global top five players had a share approximately 63.0% in terms of revenue.

paiming
Download Presentation

Global Top 13 Companies Accounted for 63% of total Azilsartan Medoxomil API market (QYResearch, 2021)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Global Market Research Report Azilsartan medoxomil (trade name Edarb) is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. It is indicated for the treatment of hypertension to lower blood pressure which reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil may be used either alone or in combination with other antihypertensive agents such as chlorthalidone (CLD). As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. Azilsartan medoxomil is a prodrug of azilsartan. It is hydrolyzed to the active moiety, azilsartan, in the gastrointestinal (GI) tract during the absorption phase. The report only studies Azilsartan Medoxomil API market, also including Azilsartan medoxomil Potassium (Azilsartan K Medoxomil) According to the new market research report “Global Azilsartan Medoxomil API Market Report 2023-2029”, published by QYResearch, the global Azilsartan Medoxomil API market size is projected to reach USD 0.07 billion by 2029, at a CAGR of 19.6% during the forecast period. Copyright © QYResearch | global@qyresearch.com | www.qyresearch.com

  2. Global Market Research Report Figure. Global Azilsartan Medoxomil API Market Size (US$ Million), 2018-2029 Above data is based on report from QYResearch: Global Azilsartan Medoxomil API Market Report 2023-2029 (published in 2023). If you need the latest data, plaese contact QYResearch.. Copyright © QYResearch | global@qyresearch.com | www.qyresearch.com

  3. Global Market Research Report Figure. Global Azilsartan Medoxomil API Top 13 Players Ranking and Market Share (Ranking is based on the revenue of 2022, continually updated) Above data is based on report from QYResearch: Global Azilsartan Medoxomil API Market Report 2023-2029 (published in 2023). If you need the latest data, plaese contact QYResearch. The global key manufacturers of Azilsartan Medoxomil API include Takeda, Metrochem API, Jubilant Pharma, Zhejiang Hongyuan, Honour Lab, HEC Pharm, Enomark, Lupin, CTX Life Sciences, Acura Labs, etc. In 2022, the global top five players had a share approximately 63.0% in terms of revenue. Copyright © QYResearch | global@qyresearch.com | www.qyresearch.com

  4. Global Market Research Report About QYResearch QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 16 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future. QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc. Copyright © QYResearch | global@qyresearch.com | www.qyresearch.com

More Related